Antibiotic Treatment for Mycoplasma genitalium-Associated PID in Australia
For M. genitalium-associated PID in Australia, treat with doxycycline 100 mg orally twice daily for 7 days followed by resistance-guided therapy: azithromycin 2.5g (1g day 1, then 500mg daily for 3 days) for macrolide-susceptible infections, or moxifloxacin 400mg daily for 7-14 days for macrolide-resistant infections.
Treatment Algorithm
Step 1: Initial Empiric Therapy
- Start doxycycline 100 mg orally twice daily for 7 days immediately while awaiting M. genitalium testing and macrolide resistance results
- Doxycycline reduces bacterial load by approximately 2.6 log10, improving subsequent antibiotic efficacy 1
- Add metronidazole 500 mg orally twice daily for 14 days to cover anaerobes and bacterial vaginosis-associated organisms commonly present in PID 2
Step 2: Resistance-Guided Sequential Therapy
If macrolide-susceptible (no resistance mutations detected):
- Azithromycin 2.5g total dose: 1g orally on day 1, then 500mg daily for 3 additional days
- This achieves 95.4-95.7% cure rates 3, 1
- De novo macrolide resistance develops in only 2.6% of cases with this regimen 3
If macrolide-resistant (resistance mutations detected):
- Moxifloxacin 400mg orally daily for 7-14 days
- Achieves 92% cure rate for macrolide-resistant infections 3
- Consider 14-day course if severe PID or tubo-ovarian abscess present
Step 3: Consider ParC-S83 Testing (Emerging Standard)
Recent 2024 Australian data shows that ParC-S83 mutation testing can further optimize moxifloxacin use 4:
- If ParC-S83 wildtype: Use moxifloxacin (89.2% cure rate)
- If ParC-S83I mutation detected: Consider alternative regimens or extended therapy
Critical Context for Australia
Resistance patterns are severe and worsening:
- Macrolide resistance exceeds 68% in Australian M. genitalium infections 1
- Moxifloxacin efficacy has declined from 100% (2015) to 79.3% (2023) 4
- ParC mutations present in 22% of macrolide-resistant cases 3
The resistance-guided approach is cost-effective: RGT reduces per-person treatment costs by AUD 34-39 compared to empiric therapy while improving cure rates 5
Important Caveats
When to Hospitalize for Parenteral Therapy
Consider inpatient IV therapy if:
- Severe illness, high fever, or signs of sepsis
- Tubo-ovarian abscess suspected
- Pregnancy
- Failed outpatient therapy after 72 hours
- Unable to tolerate oral medications
For inpatient therapy, use ceftriaxone 1g IV daily PLUS doxycycline 100mg IV/oral twice daily for 48 hours after clinical improvement, then continue oral doxycycline to complete 14 days 6. Add metronidazole for anaerobic coverage.
Testing Requirements
- Macrolide resistance testing is essential for optimal M. genitalium management in Australia 3, 1
- Test of cure recommended 14-28 days after completing antibiotics 3
- Ensure no condomless sex before test of cure to avoid reinfection confounding results
Partner Management
- Treat all sexual partners from preceding 60 days
- Partners should receive the same resistance-guided sequential therapy
- Both patient and partners must abstain from sex until treatment completion and test of cure confirms eradication
Comparison with Standard PID Regimens
While older CDC guidelines 7, 8 recommend ceftriaxone plus doxycycline ± metronidazole for general PID, these were developed before M. genitalium was widely recognized. The European guidelines 6 specifically acknowledge moxifloxacin plus ceftriaxone as first-line for M. genitalium-associated PID, though they don't detail the resistance-guided sequential approach that Australian research 3, 1 has validated.
The key distinction: Standard PID regimens treat gonorrhea, chlamydia, and anaerobes but fail to adequately address M. genitalium, particularly macrolide-resistant strains. The doxycycline lead-in followed by resistance-guided therapy specifically targets M. genitalium while maintaining coverage of other pathogens when combined with appropriate anaerobic coverage.
Monitoring and Follow-up
- Clinical improvement expected within 72 hours
- If no improvement, reassess diagnosis and consider hospitalization
- Test of cure mandatory 14-28 days post-treatment
- Rescreen for reinfection at 3-6 months given high reinfection rates